Liver Cirrhosis Network: Longitudinal and Clinical Trial Studies
Funded at University of California, San Francisco · NIH-11591424 · Data updated 2026-11-12
A network-wide NIH study focused on understanding cirrhosis better to prevent complications and improve care for people with advanced liver disease.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 6, 2021 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $393,424 |
| NIH project number | 5U01DK130168-06 |
| Project ID | NIH-11591424 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with cirrhosis or at risk for cirrhosis who are eligible for observational follow-up or clinical trials and who can participate in longitudinal data collection.
✕Less likely to help
Patients without cirrhosis or those not meeting trial/inclusion criteria may not directly benefit.
What this research studies
This program brings together longitudinal observations and clinical trials to learn how cirrhosis develops and progresses in diverse patients, including those with coexisting conditions and social challenges. It aims to identify factors that influence outcomes and to test potential therapies that could slow or halt liver damage. By studying clinical risk, biomarkers, and social determinants of health, the network seeks to uncover opportunities to prevent liver failure and liver cancer. The work is centered at the University of California, San Francisco, with collaboration across clinical sites.
Why it matters
Potential benefit: If successful, this research could lead to better prediction of complications, new preventive strategies, and improved treatment options for people with cirrhosis.
How similar studies have gone: Previous work in cirrhosis has linked biomarkers and risk factors to outcomes, supporting the potential for meaningful advances in this area.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Khalili, Mandana — University of California, San Francisco
- Study coordinator: Khalili, Mandana
Related research
Other NIH-funded projects on the same topics.
-
Liver Cirrhosis Network: Centers for Clinical Research
A multicenter study in people with cirrhosis from different causes (including HIV, NASH, and alcohol-related liver disease) to collect data and samples and test new ways to predict and monitor disease progression.
-
Liver Cirrhosis Network: Mayo Clinic's Clinical Research Center
A Mayo Clinic-led project will follow and help people with compensated cirrhosis, using data, imaging, and a big AI tool to predict when complications may happen and test whether a statin can improve outcomes.
-
Liver Cirrhosis Network: Coordinating Data for Better Care
A national effort is coordinating data to improve care for people with advanced liver disease and its complications.
-
Liver Cirrhosis Network coordinating cirrhosis studies and a rosuvastatin trial
This project follows people with liver cirrhosis over time and tests whether the cholesterol medicine rosuvastatin helps people with cirrhosis.
-
First-in-class treatment for liver cirrhosis with portal hypertension
A new therapy called XFB19 aims to reduce liver inflammation and scarring in people with advanced liver disease and portal hypertension.
-
Liver cirrhosis network coordinating treatments and patient data
This program brings hospitals together to run and organize tests of treatments and care approaches for people living with liver cirrhosis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.